Sosei Appoints David Chiswell as Non-Executive Chairman
Sosei Co. Ltd. announced the appointment of Dr. David Chiswell as Non-Executive Chairman.
David Chiswell was a founder and, from 1996 to 2002, the CEO of Cambridge Antibody Technology (CAT). Currently David is Chairman of the UK's BioIndustry Association (BIA). In addition, he is Chairman of Arrow Therapeutics Ltd and a non-executive director of Arakis Ltd. David is also an advisor to a number of private equity funds including Nomura Phase 4 Ventures. His previous experience was gained with Amersham International as well as within research posts at various institutions including the Medical Research Council, UCLA and the Imperial Cancer Research Fund.
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Infection control certification associated with lower MRSA infection rates
Full-length genome sequencing of Zika from a patient could help unlock the virus’s secrets
Codexis to Establish New R&D Facility in Singapore to Support Expanding Generics Business
AVI BioPharma Presents Antisense Approach to Transplant Acceptance By Regulating Activated Lymphocytes

Can a common heart condition cause sudden death? - A new model system offers clues
Dyax Corp. Announces First Market Approval from Licensing and Funded Research Program - Peptide ligand used in purification process during manufacture of Wyeth's XYNTHA
Change in Senior Management of WILEX AG
In scientific first, researchers visualize naturally occurring mRNA
SEQUENOM Announces Gene Expression Agreement With the University of Tuebingen - MassARRAY(TM) Compact System Reference Site Established
Biocartis strenghtens management team with new CFO
